Abstract

Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload

Obiero CW, Williams P, Murunga S, Thitiri J, Omollo R, Walker AS, Egondi T, Nyaoke B, Correia E, Kane Z, Gastine S, Kipper K, Standing JF, Ellis S, Sharland M, Berkley JA, NeoFosfo Study Group
Arch Dis Child. 2022;107

Permenent descriptor
https://doi.org/10.1136/archdischild-2021-322483


OBJECTIVE: To assess pharmacokinetics and changes to sodium levels in addition to adverse events (AEs) associated with fosfomycin among neonates with clinical sepsis. DESIGN: A single-centre open-label randomised controlled trial. SETTING: Kilifi County Hospital, Kenya. PATIENTS: 120 neonates aged

Publication metrics
Dimensions Badge

Altmetric

Key Terms
Anti-Bacterial Agents/adverse effects | Child | *Fosfomycin/adverse effects | Gentamicins | Humans | Infant | Infant, Newborn | *Neonatal Sepsis/drug therapy | *Sepsis/drug therapy | Sodium/therapeutic use (Source: Medline)
Funded by
DNDi/GARDP; German Federal Ministry of Education and Research (BMBF); German Ministry of Health; South African Medical Research Council; Department for International Development (DFID) UK; Medecins Sans Frontieres; Ministry of Health, Welfare and Sport of the Netherlands; Wellcome Trust [203077_Z_16_Z]; UK Medical Research Council (MRC) Fellowship [M008665]; MRC/DfID/Wellcome Joint Global Health Trials scheme [MR/M007367/1]
External Sources
Abstract at pubmed
Full text at publishers website
Full text at PMC